Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLSINASDAQ:OGINASDAQ:RVPHNASDAQ:TLSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLSIGreenwich LifeSciences$9.25-1.1%$11.81$8.83▼$18.75$121.59M1.6937,497 shs207,280 shsOGIOrganigram$0.98-4.8%$1.24$0.95▼$2.37$130.04M1.1818,857 shs625,785 shsRVPHReviva Pharmaceuticals$0.56+0.6%$1.43$0.50▼$4.28$18.84M-0.091.10 million shs806,140 shsTLSATiziana Life Sciences$1.02-8.1%$1.04$0.41▼$1.91$119.19M0.54454,061 shs293,092 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLSIGreenwich LifeSciences-1.07%-13.63%-22.59%-28.18%-47.80%OGIOrganigram-4.79%-7.48%-10.85%-41.63%-57.17%RVPHReviva Pharmaceuticals+0.32%-48.30%-54.92%-70.34%-84.60%TLSATiziana Life Sciences-8.11%-10.53%-11.30%+39.73%+133.68%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGLSIGreenwich LifeSciences1.664 of 5 stars3.50.00.00.02.03.30.0OGIOrganigram0.5535 of 5 stars0.02.00.00.02.20.01.3RVPHReviva Pharmaceuticals3.9374 of 5 stars4.64.00.00.02.43.30.6TLSATiziana Life Sciences0.7751 of 5 stars0.03.00.00.03.21.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLSIGreenwich LifeSciences 3.00Buy$38.00310.81% UpsideOGIOrganigram 3.00BuyN/AN/ARVPHReviva Pharmaceuticals 3.29Buy$10.001,674.62% UpsideTLSATiziana Life Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RVPH, OGI, TLSA, and GLSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $8.002/11/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.001/22/2025RVPHReviva PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $11.001/21/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.001/10/2025RVPHReviva PharmaceuticalsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy1/10/2025RVPHReviva PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$7.001/10/2025RVPHReviva PharmaceuticalsRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$7.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.52 per shareN/AOGIOrganigram$166.12M0.75N/AN/A$1.83 per share0.54RVPHReviva PharmaceuticalsN/AN/AN/AN/A$0.20 per shareN/ATLSATiziana Life SciencesN/AN/AN/AN/A$0.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLSIGreenwich LifeSciences-$8.89M-$0.80N/AN/AN/AN/A-185.12%-164.27%4/21/2025 (Estimated)OGIOrganigram-$33.39M-$0.38N/AN/AN/A-31.69%-8.59%-6.54%5/13/2025 (Estimated)RVPHReviva Pharmaceuticals-$39.26M-$1.11N/AN/AN/AN/AN/A-252.53%4/21/2025 (Estimated)TLSATiziana Life Sciences-$17.69MN/A0.00∞N/AN/AN/AN/AN/ALatest RVPH, OGI, TLSA, and GLSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/21/2025N/AGLSIGreenwich LifeSciences-$0.21N/AN/AN/AN/AN/A4/21/2025N/ARVPHReviva Pharmaceuticals-$0.22N/AN/AN/AN/AN/A3/31/2025Q4 2024RVPHReviva Pharmaceuticals-$0.22-$0.15+$0.07-$0.15N/AN/A2/11/2025Q1 2025OGIOrganigram-$0.03-$0.05-$0.02-$0.14$48.94 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AOGIOrganigramN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLSIGreenwich LifeSciencesN/A6.916.91OGIOrganigramN/A3.361.85RVPHReviva PharmaceuticalsN/A0.390.39TLSATiziana Life SciencesN/A0.85N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLSIGreenwich LifeSciences4.16%OGIOrganigram34.63%RVPHReviva Pharmaceuticals63.18%TLSATiziana Life SciencesN/AInsider OwnershipCompanyInsider OwnershipGLSIGreenwich LifeSciences51.67%OGIOrganigram0.09%RVPHReviva Pharmaceuticals27.18%TLSATiziana Life Sciences39.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLSIGreenwich LifeSciences313.15 million6.35 millionNot OptionableOGIOrganigram860126.26 million126.10 millionOptionableRVPHReviva Pharmaceuticals533.44 million24.35 millionOptionableTLSATiziana Life Sciences8116.85 million63.43 millionOptionableRVPH, OGI, TLSA, and GLSI HeadlinesRecent News About These CompaniesTiziana Life announces dosing at JHU, part of Phase 2 trial of foralumabApril 3 at 5:51 AM | markets.businessinsider.comTiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns HopkinsApril 2 at 9:04 AM | proactiveinvestors.comTiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical TrialApril 2 at 8:00 AM | globenewswire.comShort Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Rises By 42.5%March 31, 2025 | marketbeat.comTiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMSMarch 25, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis TrialMarch 25, 2025 | globenewswire.comTiziana Life Sciences to Present at the 37th Annual Roth ConferenceMarch 17, 2025 | globenewswire.comTiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Down 39.2% in FebruaryMarch 16, 2025 | marketbeat.comTiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price RuleMarch 14, 2025 | globenewswire.comTiziana seeking FDA OK to launch clinical trial of foralumab in ALSMarch 7, 2025 | alsnewstoday.comTiziana: Foralumab Drug Development Presses On With Additional EAP EnrollmentMarch 6, 2025 | seekingalpha.comTiziana submits FDA investigational new drug applicationMarch 4, 2025 | proactiveinvestors.comTiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical TrialMarch 4, 2025 | globenewswire.comTiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Drop in Short InterestMarch 4, 2025 | marketbeat.comWhy Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025March 2, 2025 | insidermonkey.comTiziana Life Sciences nasal anti-CD3 therapy shows promise in treating traumatic brain injury, study revealsFebruary 27, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain InjuryFebruary 27, 2025 | globenewswire.comTiziana Life Sciences expects to complete Long Covid study in Q2February 25, 2025 | markets.businessinsider.comTiziana Life Sciences nearing completion of long COVID study on foralumabFebruary 25, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Long Covid Study to Complete in Second QuarterFebruary 25, 2025 | globenewswire.comTiziana Life Sciences advances foralumab towards commercialization with key manufacturing partnershipFebruary 21, 2025 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?By Nathan Reiff | March 24, 2025View D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?D-Wave and Quantum Supremacy: Implications For InvestorsBy Nathan Reiff | March 19, 2025View D-Wave and Quantum Supremacy: Implications For InvestorsPalantir’s Deal With Archer Aviation Keeps AI’s Future in FocusBy Chris Markoch | March 14, 2025View Palantir’s Deal With Archer Aviation Keeps AI’s Future in Focus3 Server Stocks Set to Capture $40B in AI Revenue in 2025By Leo Miller | March 6, 2025View 3 Server Stocks Set to Capture $40B in AI Revenue in 2025Quantum Gamble? Is IonQ's Stock an Opportunity or a Mirage?By Jeffrey Neal Johnson | March 25, 2025View Quantum Gamble? Is IonQ's Stock an Opportunity or a Mirage?RVPH, OGI, TLSA, and GLSI Company DescriptionsGreenwich LifeSciences NASDAQ:GLSI$9.25 -0.10 (-1.07%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$9.25 0.00 (0.00%) As of 04/3/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Organigram NASDAQ:OGI$0.98 -0.05 (-4.79%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$0.98 +0.00 (+0.44%) As of 04/3/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Reviva Pharmaceuticals NASDAQ:RVPH$0.56 +0.00 (+0.63%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$0.57 +0.01 (+2.04%) As of 04/3/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.Tiziana Life Sciences NASDAQ:TLSA$1.02 -0.09 (-8.11%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$1.02 0.00 (-0.39%) As of 04/3/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum 5 Reasons Why Halliburton Is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Equinix: A Smart Bet on Data Centers, Dividends, and AI Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
